Open-label Trial in Parkinson's Disease (PD) (TEMPO-4)
58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)
Sponsor: AbbVie
This PHASE3 trial investigates Parkinson Disease and is currently completed. AbbVie leads this study, which shows 21 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
21 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 16 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
May 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2024 — May 2024 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2023 — Feb 2024 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2023 — Dec 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Enrolling By Invitation PHASE3
Status: Recruiting → Enrolling By Invitation
-
Nov 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE3
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adventura, United States , Albany, United States , Ancona, Italy , Asheville, United States , Augusta, United States , Bad Homburg, Germany , Barcelona, Spain , Belgrade, Serbia , Berlin, Germany , Birmingham, United States and 104 more locations